Overview

* Natera Q3 2025 revenue grows 34.7% yr/yr, beating analyst expectations

* Company raises 2025 revenue guidance by $160 mln at the midpoint

* Natera ( NTRA ) reports Q3 net loss of $87.5 mln due to higher operating expenses

Outlook

* Natera ( NTRA ) raises 2025 annual revenue guidance to $2.18 bln - $2.26 bln

* Company expects 2025 gross margin to be approximately 62% to 64%

* Natera ( NTRA ) forecasts net cash inflow of approximately $100 mln for 2025

Result Drivers

* PRODUCT REVENUE GROWTH - Driven by increased volume and average selling price improvements, as well as excess cash receipts for prior tests

* TEST VOLUME INCREASE - Processed 15.2% more tests compared to Q3 2024, including record growth in oncology tests

* GROSS MARGIN IMPROVEMENT - Higher revenues and reduced costs of test processing contributed to improved gross margins

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $592.20 $512.75

Revenue mln mln (18

Analysts

)

Q3 Net -$87.50

Income mln

Q3 -$97.60

Income mln

from

Operatio

ns

Q3 $482 mln

Operatin

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 19 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the healthcare facilities & services peer group is "buy"

* Wall Street's median 12-month price target for Natera Inc ( NTRA ) is $200.00, about 0% above its November 5 closing price of $199.92

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)